{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:45:23Z","timestamp":1767149123750,"version":"build-2238731810"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["8160-3337"],"award-info":[{"award-number":["8160-3337"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["8127-4126"],"award-info":[{"award-number":["8127-4126"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Clinical medicine +x, Medical College, Qingdao University","award":["2017M38"],"award-info":[{"award-number":["2017M38"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.pharep.2018.04.006","type":"journal-article","created":{"date-parts":[[2018,4,22]],"date-time":"2018-04-22T17:08:04Z","timestamp":1524416884000},"page":"963-971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["MiR-137 suppresses tumor growth and metastasis in clear cell renal cell carcinoma"],"prefix":"10.1007","volume":"70","author":[{"given":"Meizhi","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haijun","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaili","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"2","key":"10.1016\/j.pharep.2018.04.006_bib0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.pharep.2018.04.006_bib0010","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s12013-014-0260-6","article-title":"Hispidulin potentiates the antitumor effect of sunitinib against human renal cell carcinoma in laboratory models","volume":"71","author":"Gao","year":"2015","journal-title":"Cell Biochem Biophys"},{"issue":"9669","key":"10.1016\/j.pharep.2018.04.006_bib0015","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(09)60229-4","article-title":"Renal cell carcinoma","volume":"373","author":"Rini","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pharep.2018.04.006_bib0020","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1464-410X.2006.06616.x","article-title":"The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol","volume":"99","author":"Antonelli","year":"2007","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.pharep.2018.04.006_bib0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.pharep.2018.04.006_bib0030","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus: interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pharep.2018.04.006_bib0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"9637","key":"10.1016\/j.pharep.2018.04.006_bib0040","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pharep.2018.04.006_bib0045","first-page":"717","article-title":"Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer","volume":"30","author":"Singhal","year":"2007","journal-title":"Int J Oncol"},{"issue":"6","key":"10.1016\/j.pharep.2018.04.006_bib0050","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/ijc.24767","article-title":"Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer","volume":"126","author":"Singhal","year":"2010","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.pharep.2018.04.006_bib0055","first-page":"191","article-title":"Functional reconstitution of RLIP76 catalyzing ATP-dependent transport of glutathione-conjugates","volume":"34","author":"Singhal","year":"2009","journal-title":"Int J Oncol"},{"issue":"4","key":"10.1016\/j.pharep.2018.04.006_bib0060","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.bbrc.2005.01.055","article-title":"POB1 over-expression inhibits RLIP76-mediated transport of glutathione-conjugates: drugs and promotes apoptosis","volume":"328","author":"Yadav","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.pharep.2018.04.006_bib0065","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.canlet.2009.03.033","article-title":"Increased expression of cdc2 inhibits transport function of RLIP76 and promotes apoptosis","volume":"283","author":"Singhal","year":"2009","journal-title":"Cancer Lett"},{"issue":"19","key":"10.1016\/j.pharep.2018.04.006_bib0070","doi-asserted-by":"crossref","first-page":"17299","DOI":"10.1074\/jbc.M300788200","article-title":"HSF-1 interacts with Ral-binding protein 1 in a stress-responsive: multiprotein complex with HSP90 in vivo","volume":"278","author":"Hu","year":"2003","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.pharep.2018.04.006_bib0075","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/carcin\/bgs401","article-title":"RLIP76 is overexpressed in human glioblastomas and is required for proliferation: tumorigenesis and suppression of apoptosis","volume":"34","author":"Wang","year":"2013","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.pharep.2018.04.006_bib0080","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s12013-014-0237-5","article-title":"RLIP76 blockade by siRNA inhibits proliferation: enhances apoptosis, and suppresses invasion in HT29 colon cancer cells","volume":"71","author":"Zhang","year":"2015","journal-title":"Cell Biochem Biophys"},{"issue":"9","key":"10.1016\/j.pharep.2018.04.006_bib0085","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1158\/0008-5472.CAN-06-4124","article-title":"Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1)","volume":"67","author":"Singhal","year":"2007","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.pharep.2018.04.006_bib0090","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.cell.2009.02.005","article-title":"MicroRNAs and cancer: short RNAs go a long way","volume":"136","author":"Ventura","year":"2009","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharep.2018.04.006_bib0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.febslet.2012.11.004","article-title":"miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6","volume":"587","author":"Zhu","year":"2013","journal-title":"FEBS Lett"},{"issue":"17","key":"10.1016\/j.pharep.2018.04.006_bib0100","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1016\/j.febslet.2014.07.012","article-title":"miR-137 effects on gastric carcinogenesis are mediated by targeting Cox-2-activated PI3K\/AKT signaling pathway","volume":"588","author":"Cheng","year":"2014","journal-title":"FEBS Lett"},{"issue":"6","key":"10.1016\/j.pharep.2018.04.006_bib0105","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/ijc.25452","article-title":"miR-137 targets Cdc42 expression: induces cell cycle G1 arrest and inhibits invasion in colorectal cancer cells","volume":"128","author":"Liu","year":"2011","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.pharep.2018.04.006_bib0110","doi-asserted-by":"crossref","first-page":"e39102","DOI":"10.1371\/journal.pone.0039102","article-title":"MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells","volume":"7","author":"Zhao","year":"2012","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.pharep.2018.04.006_bib0115","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1158\/0008-5472.CAN-14-3011","article-title":"NOS inhibition modulates immune polarization and improves radiation-induced tumor growth delay","volume":"75","author":"Ridnour","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharep.2018.04.006_bib0120","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.biopha.2016.09.022","article-title":"Upregulation of miR-124 by physcion 8-O-beta-glucopyranoside inhibits proliferation and invasion of malignant melanoma cells via repressing RLIP76","volume":"84","author":"Zhang","year":"2016","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"10.1016\/j.pharep.2018.04.006_bib0125","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0092-8674(03)01018-3","article-title":"Prediction of mammalian microRNA targets","volume":"115","author":"Lewis","year":"2003","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.pharep.2018.04.006_bib0130","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1371\/journal.pbio.0020363","article-title":"Human microRNA targets","volume":"2","author":"John","year":"2004","journal-title":"PLoS Biol"},{"key":"10.1016\/j.pharep.2018.04.006_bib0135","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1101\/sqb.2006.71.013","article-title":"MicroRNAs silence gene expression by repressing protein expression and\/or by promoting mRNA decay","volume":"71","author":"Behm-Ansmant","year":"2006","journal-title":"Cold Spring Harb Symp Quant Biol"},{"issue":"2","key":"10.1016\/j.pharep.2018.04.006_bib0140","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1172\/JCI43897","article-title":"A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma","volume":"121","author":"Ory","year":"2011","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.pharep.2018.04.006_bib0145","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1074\/jbc.M113.526152","article-title":"Receptor-interacting protein 1 increases chemoresistance by maintaining inhibitor of apoptosis protein levels and reducing reactive oxygen species through a microRNA-146a-mediated catalase pathway","volume":"289","author":"Wang","year":"2014","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.pharep.2018.04.006_bib0150","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/ijc.28774","article-title":"miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6","volume":"135","author":"Zhu","year":"2014","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.pharep.2018.04.006_bib0155","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.canlet.2013.11.004","article-title":"MiR-200, a new star miRNA in human cancer","volume":"344","author":"Feng","year":"2014","journal-title":"Cancer Lett"},{"issue":"11","key":"10.1016\/j.pharep.2018.04.006_bib0160","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/stem.741","article-title":"MicroRNA-451 is involved in the self-renewal: tumorigenicity, and chemoresistance of colorectal cancer stem cells","volume":"29","author":"Bitarte","year":"2011","journal-title":"Stem Cells"},{"issue":"4","key":"10.1016\/j.pharep.2018.04.006_bib0165","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/mc.22287","article-title":"Epigenetic silencing of miR-137 is a frequent event in gastric carcinogenesis","volume":"55","author":"Steponaitiene","year":"2016","journal-title":"Mol Carcinog"},{"issue":"16","key":"10.1016\/j.pharep.2018.04.006_bib0170","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1158\/0008-5472.CAN-10-0622","article-title":"Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis","volume":"70","author":"Balaguer","year":"2010","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.pharep.2018.04.006_bib0175","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1167\/iovs.10-5272","article-title":"Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma","volume":"52","author":"Chen","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"26","key":"10.1016\/j.pharep.2018.04.006_bib0180","doi-asserted-by":"crossref","first-page":"22048","DOI":"10.18632\/oncotarget.4218","article-title":"A contrasting function for miR-137 in embryonic mammogenesis and adult breast carcinogenesis","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"issue":"14","key":"10.1016\/j.pharep.2018.04.006_bib0185","doi-asserted-by":"crossref","first-page":"12558","DOI":"10.18632\/oncotarget.3726","article-title":"Tumor suppressive microRNA-137 negatively regulates Musashi-1 and colorectal cancer progression","volume":"6","author":"Smith","year":"2015","journal-title":"Oncotarget"},{"issue":"16","key":"10.1016\/j.pharep.2018.04.006_bib0190","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1016\/j.ejca.2012.02.007","article-title":"miR-137 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2","volume":"48","author":"Chen","year":"2012","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.pharep.2018.04.006_bib0195","first-page":"541","article-title":"Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer","volume":"33","author":"Svoboda","year":"2008","journal-title":"Int J Oncol"},{"issue":"1","key":"10.1016\/j.pharep.2018.04.006_bib0200","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ccr.2007.12.008","article-title":"MicroRNA signature predicts survival and relapse in lung cancer","volume":"13","author":"Yu","year":"2008","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.pharep.2018.04.006_bib0205","first-page":"1317","article-title":"Oncogenic miR-137 contributes to cisplatin resistance via repressing CASP3 in lung adenocarcinoma","volume":"6","author":"Su","year":"2016","journal-title":"Am J Cancer Res"},{"issue":"1","key":"10.1016\/j.pharep.2018.04.006_bib0210","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3892\/ol.2016.4616","article-title":"miR-137 inhibits renal cell carcinoma growth in vitro and in vivo","volume":"12","author":"Zhang","year":"2016","journal-title":"Oncol Lett"},{"issue":"12","key":"10.1016\/j.pharep.2018.04.006_bib0215","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/exd.12812","article-title":"miR-137 inhibits proliferation of melanoma cells by targeting PAK2","volume":"24","author":"Hao","year":"2015","journal-title":"Exp Dermatol"},{"issue":"3","key":"10.1016\/j.pharep.2018.04.006_bib0220","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s11060-015-1753-x","article-title":"MiR-137 inhibits proliferation and angiogenesis of human glioblastoma cells by targeting EZH2","volume":"122","author":"Sun","year":"2015","journal-title":"J Neurooncol"},{"issue":"10","key":"10.1016\/j.pharep.2018.04.006_bib0225","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1158\/0008-5472.CAN-08-3521","article-title":"RLIP76: a target for kidney cancer therapy","volume":"69","author":"Singhal","year":"2009","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.pharep.2018.04.006_bib0230","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.bcp.2008.11.013","article-title":"Regression of prostate cancer xenografts by RLIP76 depletion","volume":"77","author":"Singhal","year":"2009","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.pharep.2018.04.006_bib0235","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1158\/0008-5472.CAN-05-3534","article-title":"Regression of melanoma in a murine model by RLIP76 depletion","volume":"66","author":"Singhal","year":"2006","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.pharep.2018.04.006_bib0240","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.bcp.2013.02.012","article-title":"P300 regulates the human RLIP76 promoter activity and gene expression","volume":"85","author":"Sehrawat","year":"2013","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.pharep.2018.04.006_bib0245","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.bbrc.2015.06.032","article-title":"RLIP76-dependent suppression of PI3K\/AKT\/Bcl-2 pathway by miR-101 induces apoptosis in prostate cancer","volume":"463","author":"Yang","year":"2015","journal-title":"Biochem Biophys Res Commun"}],"updated-by":[{"DOI":"10.1007\/s43440-020-00173-4","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"record-id":"26998"},{"DOI":"10.1007\/s43440-020-00173-4","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000}}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114017307892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114017307892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:37:39Z","timestamp":1752611859000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2018.04.006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1734114017307892"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2018.04.006","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MiR-137 suppresses tumor growth and metastasis in clear cell renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2018.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}